| Literature DB >> 17274816 |
Christèle Dubourg1, Claude Bendavid, Laurent Pasquier, Catherine Henry, Sylvie Odent, Véronique David.
Abstract
Holoprosencephaly (HPE) is a complex brain malformation resulting from incomplete cleavage of the prosencephalon, occurring between the 18th and the 28th day of gestation and affecting both the forebrain and the face. It is estimated to occur in 1/16,000 live births and 1/250 conceptuses. Three ranges of increasing severity are described: lobar, semi-lobar and alobar HPE. Another milder subtype of HPE called middle interhemispheric variant (MIHF) or syntelencephaly is also reported. In most of the cases, facial anomalies are observed in HPE, like cyclopia, proboscis, median or bilateral cleft lip/palate in severe forms, ocular hypotelorism or solitary median maxillary central incisor in minor forms. These latter midline defects can occur without the cerebral malformations and then are called microforms. Children with HPE have many medical problems: developmental delay and feeding difficulties, epilepsy, instability of temperature, heart rate and respiration. Endocrine disorders like diabetes insipidus, adrenal hypoplasia, hypogonadism, thyroid hypoplasia and growth hormone deficiency are frequent. To date, seven genes have been positively implicated in HPE: Sonic hedgehog (SHH), ZIC2, SIX3, TGIF, PTCH, GLI2 and TDGF1. A molecular diagnosis can be performed by gene sequencing and allele quantification for the four main genes SHH, ZIC2, SIX3 and TGIF. Major rearrangements of the subtelomeres can also be identified by multiplex ligation-dependent probe amplification (MLPA). Nevertheless, in about 70% of cases, the molecular basis of the disease remains unknown, suggesting the existence of several other candidate genes or environmental factors. Consequently, a "multiple-hit hypothesis" of genetic and/or environmental factors (like maternal diabetes) has been proposed to account for the extreme clinical variability. In a practical approach, prenatal diagnosis is based on ultrasound and magnetic resonance imaging (MRI) rather than on molecular diagnosis. Treatment is symptomatic and supportive, and requires a multidisciplinary management. Child outcome depends on the HPE severity and the medical and neurological complications associated. Severely affected children have a very poor prognosis. Mildly affected children may exhibit few symptoms and may live a normal life.Entities:
Mesh:
Year: 2007 PMID: 17274816 PMCID: PMC1802747 DOI: 10.1186/1750-1172-2-8
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Anatomic classification of HPE -Different levels of severity [1] [6]
| ALOBAR (complete) | Small single forebrain ventricle |
| SEMI-LOBAR | Rudimentary cerebral lobes |
| LOBAR | Fully-developed cerebral lobes |
| MIHF | Failure of separation of the posterior frontal and parietal lobes |
"The face often predicts the brain" [5, 110]. Parallelism of face and brain phenotypes generally observed in HPE.
| Group | Morphology | HPE degree |
| (I) Cyclopia | Single or double eye | Alobar |
| (II) Ethmocephaly | Distinct sockets | Alobar |
| (III) Cebocephaly | Ocular hypotelorism | Alobar |
| (IVA) | Ocular hypotelorism | Alobar |
| (IVB) | Ocular hypotelorism | Semi-lobar |
Syndromic HPE with normal karyotype
| CHARGE syndrome gene CHD7 8q12 | |
| Pallister Hall gene GLI3 7p13 | |
| Smith Lemli Opitz DHCR7 11q12-q13 | |
| Rubinstein-Taybi gene CREBBP 16p11.3 | |
| Meckel syndrome | |
| Pseudotrisomy 13 | |
| Velo cardio facial Synd gene TBX1 22q11.2 | |
| HPE and fetal akynesia, X linked? | |
| HPE, ectrodactyly, cleft lip/palate, X linked? | |
| Osteopathia striata with cranial sclerosis Xp11.4-p11.22 | |
| Lambotte syndrome | |
| Steinfeld Syndrome | |
| HPE, amelia, facial cleft | |
| Microtia-anotia | |
| Hydrolethalus syndrome | |
| Microphtalmia syndromic | |
| MLRD association | |
| Dysgnathia complex | |
| Genoa Syndrome | |
Figure 1Signaling pathways of the main HPE genes or candidate genes. All the parts of these pathways are not necessarily in the same tissue or cell type.
Known genes and candidate genes for HPE
| HPE1 21q22.3 | |||
| HPE2 2p21 SIX3 | LSS 21q22,3 HPE1 | ||
| HPE3 7q36 SHH | CFC1 2q21.1 | ||
| HPE4 18p11.3 TGIF | SIL 1p32 | ||
| HPE5 13q32 ZIC2 | DKK1 10q11.2 | ||
| HPE6 2q37.1–q37.3 | |||
| HPE7 9q22.3 PTCH | TMEM1 21q22.3 | ||
| HPE8 14q prox | FOXA2 20p11 | ||
| - | HPE9 20p13 | DISP1 1q42 | |
| - | HPE10 1q42-qter | EAPP 14q13 HPE8 | |
| - | HPE11 5pter | TECT1 12q24.1 | |
| - | HPE12 6q26-qter | CHRD 3q27 | |
| gene SHH 7q36 | NOG 17q22 | ||
| gene TGIF 18p11.3 | LPR2 2q24–q31 | ||
| gene ZIC2 13q32 | SMO 7q32.2 | ||
| gene SIX3 2p21 | HHIP 4q31.22 | ||
| gene TDGF1 3p23-p21 | BMP4 14q22.2 | ||
| gene PTCH 9q22 | NODAL 10q22.1 | ||
| gene FOXH1 8q24.3 | SMAD2/4 18q21 | ||
| gene GLI2 2q14 | CDO 11q23-q24 | ||
| TWSG1 18p11.3 | |||
Figure 2Molecular diagnosis of HPE.